Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment-Reference-Cited by-同舟云学术

Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment

Published:2024-01-01 Issue:1 Volume:10 Page:131
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Huntjens Daan W.¹²,Vanhommerig Joost W.³,van de Veen Willem⁴,Crul Mirjam¹

Affiliation:

1. Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, Amsterdam, the Netherlands

2. Department of Clinical Pharmacy, OLVG Hospital, Amsterdam, the Netherlands

3. Department of Research and Epidemiology, OLVG Hospital, Amsterdam, the Netherlands

4. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland

Abstract

This cohort study conducted in the Netherlands uses electronic medical records to assess incidence of hypersensitivity reactions with and without H2-receptor antagonist premedication before paclitaxel administration.

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2811412/jamaoncology_huntjens_2023_ld_230018_1704491813.17134.pdf

Reference6 articles.

1. Paclitaxel premedication regimens.;Boehm;J Natl Cancer Inst,1996

2. The added value of H2 antagonists in premedication regimens during paclitaxel treatment.;Cox;Br J Cancer,2021

3. Efficacy of premedication protocol without ranitidine for taxane regimen: a multicenter non-randomized historical controlled study.;Chantharakhit;Asian Pac J Cancer Prev,2022

4. General and epidemiological aspects of allergic drug reactions.;Barranco;Clin Exp Allergy,1998

5. Risk factors for drug allergy.;Adkinson;J Allergy Clin Immunol,1984

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study;JCO Oncology Practice;2024-09

2. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy;Expert Review of Clinical Pharmacology;2024-04-23